Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System
24.6.2021 20:17:00 EEST | Business Wire | Press release
Invivoscribe, a global leader in precision diagnostics, has announced the launch of an Immune Biomarker Discovery grant program, focused on supporting development, validation and deployment of novel applications for use of their distributed LymphoTrack® NGS products and bioinformatics software.
Massively parallel sequencing coupled with reagents targeting the immune receptor loci have accelerated our understanding of the immune response and immunology related disease processes. The availability of distributed RUO LymphoTrack tests and bioinformatics have eliminated a majority of the barriers of a service model approach, and have accelerated the ability to identify, track and monitor biomarkers associated with hematologic malignancies. These products are also being deployed worldwide to track the manufacture and treatment of immunotherapy, such as CAR T-cell therapies, and provide a comprehensive way to track a subject’s immune response to disease processes and to vaccines.
In conversations with customers and partners worldwide, we have also realized that our Research Use Only (RUO) LymphoTrack® sequencing kits and services also have utility far beyond clinical oncology, as these assays and software products are currently being used in research in areas as diverse as, studies of celiac disease and other autoimmune diseases, tracking the immune health of astronauts on the ISS, examining the immune response throughout the course of clinical treatments, and identifying changes in the immune repertoire with onset and progression of disease. Intrigued to learn what innovative applications our RUO LymphoTrack kits and services are being used for, we decided to launch this grant program to support these endeavors.
Successful innovative proposals submitted by applicants to our Invivoscribe’s Immune Biomarker Discovery grant program will receive LymphoTrack kits, controls and software to support their R&D project. Grants will be awarded to support cutting-edge research and development in academic, government and early-stage commercial laboratories conducting promising research studies.
“The combined costs of library preparation reagents, NGS sequencing reagents, and development of bioinformatics software represent an obstacle for researchers. The idea of this grant program is to reduce these financial barriers, thus empowering a few progressive laboratories to bring their groundbreaking applications to fruition,” says Tony Lialin, Chief Commercial Officer at Invivoscribe. Those selected as winners of the grant will not only receive NGS products, but will be provided additional opportunities to collaborate with Invivoscribe’s global network of ISO15189 accredited LabPMM laboratories. The laboratories selected for the grant program will also be featured in upcoming webinars and will be invited to speak at a number of symposiums around the world.
Details and How to Apply/Submit a Proposal
If your laboratory is interested in applying for Invivoscribe’s Immune Biomarker Discovery grant program to improve the standard of healthcare, we encourage you to submit research proposals that focus on the development of engineered antibodies to target antigens of infectious pathogens, toxins, allergens, and malignant diseases such as cancer and autoimmune disorders. More information about the program and details about how to submit a proposal can be found at www.invivoscribe.com/NGS-Grant. Proposals will be accepted from qualified laboratories across the world through Aug. 31, 2021 and winners will be announced by September 30, 2021. Additional information about the grant program and our oncology products and services can be requested by emailing sales@invivoscribe.com.
About Invivoscribe
Invivoscribe has been Improving Lives with Precision Diagnostics® for more than twenty-five years, advancing the field of precision medicine by developing and providing standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe has significantly impacted global health, working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM), Invivoscribe has demonstrated it is an ideal partner. For additional information please visit us at www.invivoscribe.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005113/en/
Contact information
Tony Lialin
inquiry@invivoscribe.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Announces Appointment of New Chief Financial Officer16.2.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization. “Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition and his many contributions to Galderma dur
REJO brings CUBE modular device to Japan in its global premiere16.2.2026 04:00:00 EET | Press release
REJO, a pioneering global provider of heat-not-burn (HNB) solutions, today announced the global debut of REJO CUBE, its latest modular HNB device, in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215596376/en/ REJO CUBE DEVICE-Product Infographic Breaking away from conventional HNB design norms, REJO CUBE introduces a bold new device option featuring a trendy design and dual-mode inhalation experience, launching on Japan’s major e-commerce retail channels from February 16. This launch marks the brand’s latest move following REJO Mate Air’s introduction in Japan in July 2025, when the device’s compact design, smooth mouthfeel, and Puff Twice feature won widespread acclaim among local adult users. REJO CUBE speak for REJO’s ongoing commitment to placing user experience at the core of its research and development effort, bringing kit flexibility with modular design, deep user engagement with interactive features, and
Sultan bin Ahmed Visits Shanghai Film Studios, Film Park and Stadium15.2.2026 21:24:00 EET | Press release
His Highness Sheikh Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, visited the 800,000-square-metre Shanghai Film Studios and Film Park in the town of Shidon in the Chinese city of Shanghai on Saturday. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215440594/en/ Sultan bin Ahmed visits Shanghai Film Studios, Film Park and Stadium (Photo: AETOSWire) His Highness watched a video outlining the specifications of the Shanghai studios, which comprise 4 professional studios ranging in size from 800 to 3000 square metres, a large costume warehouse, production support facilities, classic cars, and an integrated set of production services. His Highness was briefed on the work produced using artificial intelligence technologies. He toured the sound recording rooms, image quality control, editing and post-production facilities, and listened to an explanation on the developme
Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management15.2.2026 19:45:00 EET | Press release
Estithmar Holding Q.P.S.C. announced today the establishment of its fifth group, “Estithmar Capital,” in a strategic step aimed at strengthening the company’s expansion and diversifying the sectors in which it operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215458570/en/ Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management (Photo: AETOSWire) Estithmar Capital will specialize in managing financial investments, strengthening institutional governance, and operating under clear frameworks for compliance, regulation, and risk management, reflecting Estithmar Holding’s vision for sustainability and responsible, well-structured growth. The establishment of Estithmar Capital supports Estithmar Holding’s broader strategy of diversifying financial assets, improving capital efficiency, and unifying governance practices across various markets. Through a centralized and disciplined approach, t
Align Partners Issues Third Public Shareholder Letter and Submits Formal Shareholder Proposals to Coway14.2.2026 13:31:00 EET | Press release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway” or the “Company”), has submitted formal shareholder proposals for the Company’s upcoming 37th Annual General Meeting (“AGM”) and issued its third public shareholder letter to Coway’s Board of Directors. Coway is South Korea’s leading home appliance rental platform, supported by a strong global brand and sales network. Since Netmarble became the largest shareholder in 2020, Coway has delivered steady operating growth, with revenue and operating profit increasing at compound annual rates of 8.9% and 7.7%, respectively, reaching KRW 5.0 trillion in revenue and KRW 878.7 billion in operating profit in 2025. However, Coway’s share price remains materially undervalued, declining 16% from 2019 levels as of February 6, 2026, despite a 155% increase in the KOSPI 200 index over the same period. Over this period, valuation multiples have also compressed significantly, with NTM PER declining from 1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom